Lilly's Orforglipron Achieves Significant Weight Loss In Phase 3 Trial
17/9 05:35
(RTTNews) - Eli Lilly and Co. (LLY) announced detailed results from its Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of orforglipron—an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist—in adults with obesity, or those overweight with a weight-re...